Skip to main content

Advertisement

Log in

Hydroxyurea in Sickle Cell Disease: Drug Review

  • Review Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Hydroxyurea, a myelosuppressive agent, is the only effective drug proven to reduce the frequency of painful episodes. It raises the level of HbF and the haemoglobin level. It usually decreases the rate of painful episodes by 50 %. It was first tested in sickle cell disease in 1984. It also decreases the rate of ACS episodes and blood transfusions by ~50 % in adults. It was developed as an anticancer drug and has been used to treat myeloproliferative syndromes-leukemia, melanoma, and ovarian cancer. It was approved for use by FDA in adults. Side effects includes neutropenia, bone marrow suppression, elevation of hepatic enzymes, anorexia, nausea, vomiting and infertility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brawley OW, Cornelius LJ, Edwards LR et al (2008) National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 148(12):932–938

    Article  PubMed  Google Scholar 

  2. Leikin SL, Gallagher D, Kinney TR et al (1989) Mortality in children and adolescents with sickle cell disease: cooperative study of sickle cell disease. Pediatrics 84(3):500–508

    CAS  PubMed  Google Scholar 

  3. Platt OS, Brambilla DJ, Rosse WF et al (1994) Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 330(23):1639–1644

    Article  CAS  PubMed  Google Scholar 

  4. Odie`vre MH, Bony V, Benkerrou M et al (2008) Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. Haematologica 93(4):502–510

    Article  CAS  Google Scholar 

  5. Gladwin MT, Shelhamer JH, Ognibene FP et al (2002) Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 116(2):436–444

    Article  CAS  PubMed  Google Scholar 

  6. Trompeter S, Roberts I (2009) Haemoglobin F modulation in childhood sickle cell disease. Br J Haematol 144(3):308–316

    Article  CAS  PubMed  Google Scholar 

  7. Hankins J, Aygun B (2009) Pharmacotherapy in sickle cell disease: state of the art and future prospects. Br J Haematol 145(3):296–308

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Kato GJ, McGowan V, Machado RF et al (2006) Lactate dehydrogenase as a biomarker of hemolysis associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107(2):2279–2285

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Charache S, Dover GJ, Moore RD et al (1992) Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 79(10):2555–2565

    CAS  PubMed  Google Scholar 

  10. Jayabose S, Tugal O, Sandoval C et al (1996) Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 129(4):559–565

    Article  CAS  PubMed  Google Scholar 

  11. de Montalembert M, Belloy M, Bernaudin F et al (1997) Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease: the French Study Group on sickle cell disease. J Pediatr Hematol Oncol 19(4):313–318

    Article  PubMed  Google Scholar 

  12. Kinney TR, Helms RW, O’Branski EE et al (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94(5):1550–1554

    CAS  PubMed  Google Scholar 

  13. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE (2001) A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 139(6):790–796

    Article  CAS  PubMed  Google Scholar 

  14. Ware RE, Eggleston B, Redding-Lallinger R et al (2002) Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99(1):10–14

    Article  CAS  PubMed  Google Scholar 

  15. Wang WC, Helms RW, Lynn HS et al (2002) Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS study. J Pediatr 140(2):225–229

    Article  CAS  PubMed  Google Scholar 

  16. de Montalembert M, Brousse V, Elie C et al (2006) Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica 91(1):125–128

    PubMed  Google Scholar 

  17. Hankins JS, Ware RE, Rogers ZR et al (2005) Longterm hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 106(7):2269–2275

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Thornburg CD, Dixon N, Burgett S et al (2008) A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer 52(5):609–615

    Article  Google Scholar 

  19. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE (2007) Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 110(3):1043–1047

    Article  CAS  PubMed  Google Scholar 

  20. Ware RE, Zimmerman SA, Schultz WH (1999) Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 94(9):3022–3026

    CAS  PubMed  Google Scholar 

  21. Ryan K, Heeney M (2004) New England pediatric sickle cell consortium, 13 May 2004

  22. Heeney MM, Whorton MR, Howard TA, Ware RE (2004) Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol 26(3):179–184

    Article  PubMed  Google Scholar 

  23. Heeney MM, Ware RE (2008) Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am 55(2):483–501

    Article  PubMed  Google Scholar 

  24. Ballas SK, McCarthy WF, Guo N et al (2009) Multicenter study of hydroxyurea in sickle cell anemia. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc 101:1046–1051

    PubMed  Google Scholar 

Download references

Conflict of Interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rakesh Kantilal Patel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agrawal, R.K., Patel, R.K., shah, V. et al. Hydroxyurea in Sickle Cell Disease: Drug Review. Indian J Hematol Blood Transfus 30, 91–96 (2014). https://doi.org/10.1007/s12288-013-0261-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-013-0261-4

Keywords

Navigation